A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Currently, there is no widely used adjuvant treatment available to improve survival after surgical excision of a primary melanoma. In a previous study, loco‐regional and systemic immune stimulations, as well as favourable clinical outcomes in terms of sentinel lymph node (SLN) tumor status and recurrence‐free survival (RFS) in patients with clinical stage I‐II melanoma who received a low dose of toll‐like receptor 9 (TLR‐9) CPG7909 (CpG‐B ODN) intradermally at the excision site of the primary tumor prior to SLN biopsy (SNB) were described. In this phase II trial the investigators had investigated the clinical activity of a next‐generation CpG‐ODN, IMO‐2125, and it's ability to induce loco‐regional and systemic immune stimulation in pT3‐4 cN0M0 melanoma patients who are scheduled to undergo a combined re‐excision and SNB is